LIGAND PHARMACEUTICALS (LGND)

Company Profile

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. The company is headquartered in San Diego, California and currently employs 76 full-time employees. The firm is focused on acquiring or funding programs and technologies that pharmaceutical companies use to discover and develop medicines. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Its Pelican Expression technology is a scalable platform for recombinant protein production, and is especially suited for complex, large-scale protein production. Its products include Kyprolis, Teriparatide, Evomela, Rylaze, Nexterone, Pneumosil, Vaxneuvance, and others. Kyprolis is formulated with its Captisol technology. Teriparatide Injection is a drug indicated for use including the treatment of osteoporosis in certain patients at high risk for fracture. Evomela is a Captisol-enabled melphalan IV formulation. The company also owns berdazimer gel and all the assets related to the NITRICIL technology platform, and rights to Sitavig program.

Company Info

LIGAND PHARMACEUTICALS

3911 Sorrento Valley Blvd, Suite 110

San Diego CALIFORNIA 92121

P: 18585507500

CEO: John L. Higgins

Employees: 76

Website: https://www.ligand.com/